Evidence map›Paper›PMID 28555259›Full record

ArticleCancer immunology, immunotherapy : CII2017

In vitro differentiated plasmacytoid dendritic cells as a tool to induce anti-leukemia activity of natural killer cells.

Yildian Díaz-Rodríguez, Paulo Cordeiro, Assila Belounis, Sabine Herblot, Michel Duval

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07518654 (Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07518654 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing (ThINKK) Adoptive Immunotherapy: Feasibility, Safety and Pharmacodynamics in Children Undergoing Allogenic Hematopoietic Transplantation for Leukemia or Neuroblastoma

TypeinterventionalSponsorMichel DuvalRan2026 to 2029Enrolled12ConditionsLeukaemia (Acute Lymphoblastic), Leukaemia (Acute Myeloid), Neuroblastoma, Neuroblastoma, MetastaticArmsTherapeutic Inducers of Natural Killer Killing (ThINKK)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Human CD34Frontiers in immunology · 2024
    Article
  4. Human CD34Cellular and molecular life sciences : CMLS · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yildian Díaz-RodríguezUnité de recherche en hémato-oncologie Charles-Bruneau, Centre de Recherche du CHU Sainte-Justine, 3175, Côte Sainte-Catherine, Montreal, QC, H3T 1C5, Canada.
Paulo CordeiroUnité de recherche en hémato-oncologie Charles-Bruneau, Centre de Recherche du CHU Sainte-Justine, 3175, Côte Sainte-Catherine, Montreal, QC, H3T 1C5, Canada.
Assila BelounisUnité de recherche en hémato-oncologie Charles-Bruneau, Centre de Recherche du CHU Sainte-Justine, 3175, Côte Sainte-Catherine, Montreal, QC, H3T 1C5, Canada.
Sabine HerblotUnité de recherche en hémato-oncologie Charles-Bruneau, Centre de Recherche du CHU Sainte-Justine, 3175, Côte Sainte-Catherine, Montreal, QC, H3T 1C5, Canada. sabine.herblot@umontreal.ca.ORCID http://orcid.org/0000-0001-8702-7262
Michel DuvalUnité de recherche en hémato-oncologie Charles-Bruneau, Centre de Recherche du CHU Sainte-Justine, 3175, Côte Sainte-Catherine, Montreal, QC, H3T 1C5, Canada.
Centre Hospitalier Universitaire Sainte-Justine · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is believed to be resistant to NK cell-mediated killing. To overcome this resistance, we developed an innovative approach based on NK cell stimulation with Toll-like receptor (TLR)-activated plasmacytoid dendritic cells (pDC). The translation of this approach into the clinic requires the production of high numbers of human pDC. Herein, we show that in vitro differentiation of cord blood CD34

Indexed as

AnimalsCell DifferentiationCell Line, TumorCells, CulturedDendritic CellsHumansImmunotherapyKiller Cells, NaturalMiceMice, Inbred NODMice, SCIDPrecursor Cell Lymphoblastic Leukemia-LymphomaAryl hydrocarbon receptor antagonistCancer immunotherapyIn vitro expansion and differentiation of hematopoietic cellsNatural killer cellsPlasmacytoid dendritic cells

Identifiers

PMID28555259
PMCPMC5626790
OpenAlexW2618639283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.